Q-omics provides the consensus-scored CA5B profile across patient tissues and cancer cell-line models. CA5B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CA5B is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CA5B RNA expression shows 19,427 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where CA5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA5B survival associations across molecular data types. CA5B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA5B RNA expression–survival associations across cancer types. High CA5B expression shows unfavorable associations in MESO, LGG and DLBC, but favorable associations in KIRC, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CA5B RNA expression.
This table summarizes CA5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CA5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA5B shows lower tumor expression in BLCA, LUSC, THCA, LUAD and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher CA5B RNA expression in normal versus tumor tissue (log2 FC = −0.987, t-test p < 0.001).
This table shows molecular features associated with CA5B in patient tissues and cancer cell lines. In patient samples, CA5B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CA5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
